Instylla's New Step Forward with Tembo Embolic System
Instylla, Inc., a clinical-stage company specializing in peripheral vascular embolotherapy, has recently announced the FDA's clearance of their Tembo™ Embolic System. This marks a significant development in the field of medical treatments aimed at vascular issues.
The Science Behind Tembo Embolic System
The Tembo Embolic System is crafted from unique, bioresorbable components that consist of irregularly shaped, dry gelatin particles. These particles range in size from 85 to 255 micrometers and are specifically designed for effective embolization targeting hypervascular tumors and blood vessels. By occluding blood flow in peripheral areas, this system offers a modern approach to dealing with various vascular conditions.
A New Era in Vascular Treatments
The application of peripheral vascular embolization has seen a tremendous evolution over the past three decades. It now covers a multitude of clinical uses, including treating vascular malformations, uterine artery, prostatic artery, and genicular artery embolizations. The Tembo Embolic System is anticipated to expand these applications further, adding a valuable tool to healthcare providers' treatment options.
Expert Insights on the Tembo System
Dr. Venkatesh Krishnasamy, a leading figure in Interventional Oncology and Associate Professor, expressed optimism about the Tembo System. He noted, "The innovations in absorbable embolics provide much-needed solutions to existing challenges with conventional permanent embolics, thanks to its high visibility and easy application." This endorsement from a reputable medical professional underscores the system's potential impact on patient care and treatment versatility.
Looking Ahead for Instylla
Amar Sawhney, the CEO of Instylla, is looking forward to introducing the Tembo Embolic System to the market in the United States. He stated, "We are proud to achieve 510(k) clearance and are working to optimize the clinical advantages our system can offer through partnerships with interventional radiology experts." This proactive approach suggests that Instylla is not only focused on bringing innovative products to market but also on ensuring they are utilized effectively in various medical situations.
Ongoing Commitment to Innovation
While the Tembo System is a thrilling milestone for Instylla, the company is also dedicated to advancing its flagship product, the Embrace™ Hydrogel Embolic System. The ambition to develop unique and resorbable embolic agents firmly positions Instylla as a forward-thinking leader in interventional radiology.
About Instylla, Inc.
Founded in 2017, Instylla, Inc. is committed to revolutionizing the field of interventional radiology through the development of new-generation embolics. With a strong backing from prominent venture capital firms, the company is focused on both clinical and technological advancements to improve patient outcomes in various therapeutic areas.
Frequently Asked Questions
What is the Tembo Embolic System?
The Tembo Embolic System is a bioresorbable embolic agent developed by Instylla, designed for occluding blood flow in peripheral vasculature.
How does the Tembo System differ from conventional embolics?
It features irregularly shaped particles that allow for easier preparation, enhanced visibility during procedures, and the ability to pack treated vessels densely.
What are the potential applications of the Tembo System?
This system can be used for a range of applications including the treatment of vascular malformations, uterine artery embolization, and hypervascular tumors.
Who leads the team at Instylla?
The company is led by Amar Sawhney, who serves as the CEO and is also the Managing Director of Incept, LLC.
What future products is Instylla developing?
In addition to the Tembo Embolic System, Instylla is focused on introducing the Embrace™ Hydrogel Embolic System to enhance treatment options in interventional radiology.
